

Alejandro Forner

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6709136/alejandro-forner-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

109
papers

28,322
citations

38
h-index

148
g-index

148
ext. papers

34,694
ext. citations

8.1
avg. IF

7.4
L-index

#	Paper	IF	Citations
109	Sorafenib in advanced hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2008 , 359, 378-90	59.2	9089
108	Hepatocellular carcinoma. <i>Lancet, The</i> , 2012 , 379, 1245-55	40	3423
107	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018 , 69, 182-236	13.4	3196
106	Hepatocellular carcinoma. <i>Lancet, The</i> , 2018 , 391, 1301-1314	40	2402
105	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology, The</i> , 2009 , 10, 35-43	21.7	1490
104	Current strategy for staging and treatment: the BCLC update and future prospects. <i>Seminars in Liver Disease</i> , 2010 , 30, 61-74	7.3	770
103	Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. <i>Journal of Hepatology</i> , 2007 , 46, 474-81	13.4	734
102	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. <i>Hepatology</i> , 2008 , 47, 97-104	11.2	718
101	Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. <i>Lancet Oncology, The</i> , 2012 , 13, e11-22	21.7	701
100	Management of HCC. <i>Journal of Hepatology</i> , 2012 , 56 Suppl 1, S75-87	13.4	438
99	Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. <i>Cancer Treatment Reviews</i> , 2011 , 37, 212-20	14.4	407
98	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. <i>Cancer</i> , 2009 , 115, 616-23	6.4	359
97	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 557-588	24.2	355
96	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , 2012 , 56, 1330-5	13.4	354
95	Treatment of intermediate-stage hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 525-35	19.4	315
94	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , 2010 , 51, 2020-9	11.2	209
93	Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2009 , 50, 791-8	11.2	207

92	Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. <i>Annual Review of Medicine</i> , 2010 , 61, 317-28	17.4	189
91	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014 , 61, 318-24	13.4	172
90	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019 , 72, 28-36	14.4	163
89	Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. <i>Hepatology</i> , 2013 , 58, 2023-31	11.2	162
88	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2010 , 10, 209	4.8	138
87	Non-invasive diagnosis of hepatocellular carcinoma \geq cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. <i>Journal of Hepatology</i> , 2012 , 56, 1317-23	13.4	135
86	BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. <i>Journal of Hepatology</i> , 2021 ,	13.4	127
85	New aspects of diagnosis and therapy of hepatocellular carcinoma. <i>Oncogene</i> , 2006 , 25, 3848-56	9.2	125
84	Treatment of hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 60, 89-98	7	123
83	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. <i>Gut</i> , 2012 , 61, 1481-7	19.2	121
82	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015 , 275, 698-707	20.5	99
81	Chemoembolization for intermediate HCC: is there proof of survival benefit?. <i>Journal of Hepatology</i> , 2012 , 56, 984-6	13.4	89
80	Biomarkers for early diagnosis of hepatocellular carcinoma. <i>Lancet Oncology</i> , 2012 , 13, 750-1	21.7	86
79	Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. <i>Hepatology</i> , 2011 , 54, 2238-44	11.2	84
78	Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. <i>Seminars in Liver Disease</i> , 2014 , 34, 444-55	7.3	83
77	Evoluci3 natural y estratificaci3 del carcinoma hepatocelular. <i>Clinical Liver Disease</i> , 2013 , 2, S33-S36	2.2	78
76	Clinical presentation, diagnosis and staging of cholangiocarcinoma. <i>Liver International</i> , 2019 , 39 Suppl 1, 98-107	7.9	77
75	Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. <i>Gastroenterology</i> , 2009 , 137, 26-9	13.3	77

74	Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. <i>Hepatology</i> , 2016 , 63, 839-49	11.2	74
73	Prognostic prediction in patients with hepatocellular carcinoma. <i>Seminars in Liver Disease</i> , 2005 , 25, 171-80	5.9	71
72	Consensus report of the Fifth International Forum for Liver MRI. <i>American Journal of Roentgenology</i> , 2013 , 201, 97-107	5.4	35
71	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 482-491	6.1	30
70	Hepatocellular carcinoma surveillance with miRNAs. <i>Lancet Oncology, The</i> , 2015 , 16, 743-5	21.7	29
69	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules. <i>Journal of Hepatology</i> , 2015 , 62, 150-5	13.4	28
68	Treatment of early hepatocellular carcinoma: Towards personalized therapy. <i>Digestive and Liver Disease</i> , 2010 , 42 Suppl 3, S242-8	3.3	27
67	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019 , 1, 17-29	10.3	26
66	Hepatocellular carcinoma [AuthorsPreply]. <i>Lancet, The</i> , 2012 , 380, 470-471	4.0	26
65	Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. <i>Hepatology</i> , 2016 , 63, 488-98	11.2	21
64	New drugs for the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2009 , 29 Suppl 1, 148-58	7.9	19
63	Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1239-44	2.2	16
62	Surveillance for hepatocellular carcinoma. <i>Baillierels Best Practice and Research in Clinical Gastroenterology</i> , 2016 , 30, 1001-1010	2.5	15
61	Prognosis prediction and staging. <i>Baillierels Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 855-65	2.5	15
60	What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?. <i>Liver Transplantation</i> , 2011 , 17 Suppl 2, S26-33	4.5	15
59	Ablation for hepatocellular carcinoma: Is there need to have a winning technique?. <i>Journal of Hepatology</i> , 2010 , 52, 310-2	13.4	15
58	Ileal carcinoid tumor as a cause of massive lower-GI bleeding: the role of capsule endoscopy. <i>Gastrointestinal Endoscopy</i> , 2004 , 60, 483-5	5.2	15
57	Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 10	19.4	14

56	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021 , 73, 2311-2325	11.2	13
55	East meets the West--portal pressure predicts outcome of surgical resection for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2009 , 6, 14-5		12
54	Transarterial chemoembolization for patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2007 , 37 Suppl 2, S230-7	5.1	12
53	New challenges in clinical research on hepatocellular carcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016 , 108, 485-93	0.9	11
52	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021 , 3, 100260	0.3	11
51	Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020 , 30, 186-194	8	11
50	IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3195-3201	5.1	10
49	Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.. <i>Journal of Hepatology</i> , 2021 ,	13.4	10
48	Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020 , 31, 710-719	2.4	10
47	Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules \geq 1 cm in cirrhosis. <i>Liver International</i> , 2019 , 39, 1281-1291	7.9	9
46	Sunitinib and the benefits of a negative study. <i>Lancet Oncology</i> , 2009 , 10, 743-4	21.7	8
45	Reply:. <i>Hepatology</i> , 2008 , 47, 2146-2147	11.2	8
44	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020 , 52, 1041-1046	3.3	7
43	Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. <i>Journal of Hepatology</i> , 2020 , 73, 1360-1367	13.4	7
42	Intermediate-stage HCC--upfront resection can be feasible. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12,	19.4	6
41	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy 2021 , 9,		6
40	The size of the problem: clinical algorithms. <i>Digestive Diseases</i> , 2013 , 31, 95-103	3.2	5
39	Transarterial therapies in HCC: does embolization increase survival?. <i>Journal of Hepatology</i> , 2009 , 51, 981-3	13.4	5

38	Natural history and staging for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012 , 1, 183-185	2.2	4
37	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2020 , 26, S1-S40	3	4
36	CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis. <i>Radiology</i> , 2021 , 211244	20.5	4
35	Does ramucirumab deserve a second chance for liver cancer?. <i>Lancet Oncology, The</i> , 2015 , 16, 751-2	21.7	3
34	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020 , 30, 6694-6701	8	3
33	Approach of the patient with a liver mass. <i>Frontline Gastroenterology</i> , 2012 , 3, 252-262	2.6	3
32	Clinical research in hepatocellular carcinoma: study design and endpoints. <i>Journal of Hepatology</i> , 2009 , 50, 850-3	13.4	3
31	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021 , 75, 1154-1163	13.4	3
30	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules \geq cm in cirrhotic patients. <i>European Radiology</i> , 2021 , 31, 4794-4803	8	3
29	Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study. <i>Liver Transplantation</i> , 2017 , 23, 645-651	4.5	2
28	PS-115-Evaluation of LI-RADS v2018 by magnetic resonance in US-detected nodules <i>Journal of Hepatology</i> , 2019 , 70, e73	13.4	2
27	Conclusive HCC diagnosis with hepatocyte-specific contrast-enhanced magnetic resonance imaging? Not yet. <i>Journal of Hepatology</i> , 2016 , 65, 648-9	13.4	2
26	To expand or not to expand the criteria for hepatocellular carcinoma transplantation: is downstaging the answer?. <i>Gastroenterology</i> , 2009 , 137, 375-6; discussion 377	13.3	2
25	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021 , 55, 263-270	3	2
24	Intention-to-treat curative liver resection in patients with "very early" intrahepatic cholangiocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2020 , 405, 967-975	3.4	2
23	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica</i> , 2021 , 156, 463.e1-463.e30	1	2
22	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	2
21	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. <i>Cancers</i> , 2022 , 14, 2389	6.6	2

20	Systemic doxorubicin and hepatocellular carcinoma: the end of an era never risen up. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 418-420	18.8	1
19	Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma?. <i>Lancet Oncology</i> , 2020 , 21, 867-869	21.7	1
18	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
17	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020 , 40, 2476-2488	7.9	1
16	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. <i>United European Gastroenterology Journal</i> , 2021 , 9, 655-661	5.3	1
15	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016 , 146, 511.e1-511.e22	0.3	1
14	REPLY. <i>Hepatology</i> , 2021 , 74, 1129-1131	11.2	1
13	Malignant Tumours 1437-1463		1
12	Hepatocarcinoma y VHC. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 196-199	0.9	0
11	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , 2021 , 12, 440-449	3.3	0
10	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021 , 156, 463.e1-463.e30	0.3	0
9	REPLY. <i>Hepatology</i> , 2021 , 74, 2319-2321	11.2	0
8	Impact of Reference Standard on CT, MRI, and Contrast-enhanced US LI-RADS Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis.. <i>Radiology</i> , 2022 , 212340	20.5	0
7	Reply to: Poor contrast enhanced ultrasonography! There is no limit to its decline in the diagnosis of hepatocellular carcinoma on cirrhosis! <i>Journal of Hepatology</i> , 2015 , 62, 1453-4	13.4	
6	Liver Transplantation for Hepatocellular Carcinoma in HCV-Infected Patients 2014 , 77-93		
5	Addendum al artículo: «Técnicas de imagen en el carcinoma hepatocelular: diagnóstico, extensión y evaluación de la respuesta terapéutica». <i>Gastroenterología Y Hepatología</i> , 2010 , 33, 727-728	0.9	
4	Reply:. <i>Hepatology</i> , 2009 , 50, 1316-1317	11.2	
3	Reply:. <i>Hepatology</i> , 2010 , 52, 1516-1517	11.2	

2 Tumors of the Liver 773-785

- 1 A rare cause of systemic inflammatory response syndrome. *Gastroenterología Y Hepatología*, 2019, 42, 383-384

0.9